154
Views
0
CrossRef citations to date
0
Altmetric
Preliminary Communication

Inhibition of Bacterial and Fungal Pathogens by the Orphaned Drug Auranofin

, , , , , , , & show all
Pages 117-132 | Received 09 Jun 2016, Accepted 17 Nov 2015, Published online: 25 Jan 2016

References

  • Cuddy SM . Methicillin-resistant Staphylococcus aureus: a new pandemic?Plast. Surg. Nurs.28 (4), 168–169 (2008).
  • Pfaller M , MesserS, JonesRN, CastanheiraM. Antifungal susceptibilities of Candida Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010–2012). J. Antibiot. (Tokyo)68 (9), 556–561 (2015).
  • Cleveland AA , HarrisonLH, FarleyMMet al. Declining Incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance. PLoS ONE10, e0120452 (2015).
  • Pan W , KhayhanK, HagenFet al. Resistance of Asian Cryptococcus neoformans serotype a is confined to few microsatellite genotypes. PLoS ONE7 (3), e32868 (2012).
  • Mdodo R , MoserSA, JaokoWet al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya. 54 (5), 1–7 (2012).
  • Bii CC , MakimuraK, AbeSet al. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses50, 25–30 (2007).
  • Bicanic T , HarrisonT, NiepiekloA, DyakopuN, MeintjesG. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin. Infect. Dis.43, 1069–1073 (2006).
  • Rajamuthiah R , FuchsBB, JayamaniEet al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS ONE9 (2), e89189 (2014).
  • Jackson-Rosario S , CowartD, MyersAet al. Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct. J. Biol. Inorg. Chem.14 (4), 507–519 (2009).
  • Rhodes MD , SadlerPJ, ScawenMD SS. Effects of Gold(I) antiarthritic drugs and related compounds on Pseudomonas putida. J. Inorg. Chem.46, 129–142 (1992).
  • Jackson-Rosario S , SelfWT. Inhibition of selenium metabolism in the oral pathogen Treponema denticola. J. Bacteriol.191 (12), 4035–4040 (2009).
  • Cell Profiler . www.cellprofiler.org/.
  • Clinical and Laboratory Standards Institute . Methods For Dilution Antimicrobial Susceptibility Tests For Bacteria That Grow Aerobically; Approved Standard (8th Edition). M07-A8., CLSI, PA, USA (2009).
  • Clinical and Laboratory Standards Institute . Reference Methods For Broth Dilution Antifungal Susceptibility Testing Of Yeast. CLSI, PA, USA (2012).
  • Rajput SB , KaruppayilSM. Small molecules inhibit growth, viability and ergosterol biosynthesis in Candida albicans. SpringerPlus2 (1), 26 (2013).
  • Orhan G , BayramA, ZerY, BalciI. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J. Clin. Microbiol.43 (1), 140–143 (2005).
  • Garsin DA , SifriCD, MylonakisEet al. A simple model host for identifying Gram-positive virulence factors. Proc. Natl Acad. Sci. USA98 (19), 10892–10897 (2001).
  • Conery AL , Larkins-FordJ, AusubelFM, KirienkoNV. High-throughput screening for novel anti-infectives using a C. elegans pathogenesis model. Curr. Protoc. Chem. Biol.6 (1), 25–37 (2014).
  • Holland TL , ArnoldC, FowlerVG. Clinical management of Staphylococcus aureus bacteremia. JAMA312 (13), 1330–1341 (2014).
  • Kean WF , HartL, BuchananWW. Auranofin. Br. J. Rheumatol.36 (5), 560–572 (1997).
  • Cassetta MI , MarzoT, FallaniS, NovelliA, MessoriL. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals27 (4), 787–791 (2014).
  • Rice LB , CariasLL, RudinS, WoodA, Hutton-ThomasR, LakticV. Enterococcus faecium low-affinity pbp5 is a transferable determinant. Antimicrob. Agents Chemother.49 (12), 5007–5012 (2005).
  • Angelucci F , SayedAA, WilliamsDLet al. Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J. Biol. Chem.284 (42), 28977–28985 (2009).
  • Tejman-Yarden N , MiyamotoY, LeitschDet al. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob. Agents Chemother.57 (5), 2029–2035 (2013).
  • Bonilla M , DenicolaA, NovoselovSVet al. Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a single thioredoxin glutathione reductase and dependent on selenium and glutathione. J. Biol. Chem.283 (26), 17898–17907 (2008).
  • Lu J , HolmgrenA. The thioredoxin antioxidant system. Free Radic. Biol. Med.66, 75–87 (2014).
  • Missall TA , LodgeJK. Thioredoxin reductase is essential for viability in the fungal pathogen Cryptococcus neoformans. Eukaryot. Cell.4 (2), 487–489 (2005).
  • Ianiri G , IndrumAL. Essential gene discovery in the Basidiomycete Cryptococcus. MBio6 (12), e02334–e02314 (2015).
  • Harbut MB , VilchèzeC, LuoXet al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc. Natl Acad. Sci. USA112 (14), 4453–4458 (2015).
  • Debnath A , ParsonageD, AndradeRMet al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nature18 (6), 956–960 (2012).
  • Lu J , Vlamis-GardikasA, KandasamyKet al. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB J.27, 1394–1403 (2013).
  • Newton GL , ArnoldK, PriceMSet al. Distribution of thiols in microorganisms: mycothiol is a major thiol in most actinomycetes. J. Bacteriol.178 (7), 1990–1995 (1996).
  • Holmgren A . Reduction of risulfides by thioredoxin. J. Biol. Chem.254 (18), 9113–9119 (1979).
  • Uziel O , BorovokI, SchreiberR, CohenG, AharonowitzY. Transcriptional regulation of the Staphylococcus aureus thioredoxin and thioredoxin reductase genes in response to oxygen and disulfide stress. J. Bacteriol.186 (2), 326–334 (2004).
  • Stylianou M , KulesskiyE, LopesJP, GranlundM, WennerbergK, UrbanCF. Antifungal application of nonantifungal drugs. Antimicrob. Agents Chemother.58 (2), 1055–1062 (2014).
  • Denning DW . Echinocandin antifungal drugs. Lancet362 (9390), 1142–1151 (2003).
  • Dismukes WE . Management of cryptococcosis. Clin. Infect. Dis.17 (Suppl. 2), S507–S512 (1993).
  • Enjalbert B . Stress-induced gene expression in Candida albicans: absence of a general stress response. Mol. Biol. Cell14 (4), 1460–1467 (2002).
  • Cuellar-Cruz M , Lopez-RomeroE, Ruiz-BacaE, Zazueta-SandovalR. Differential response of Candida albicans and Candida glabrata to oxidative and nitrosative stresses. Curr. Microbiol.69 (5), 733–739 (2014).
  • Siles SA , SrinivasanA, PierceCG, Lopez-RibotJL, RamasubramanianAK. High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob. Agents Chemother.57 (8), 3681–3687 (2013).
  • Ozdemir I , TemelliN, GünalS, DemirS. Gold(I) complexes of N-heterocyclic carbene ligands containing benzimidazole: synthesis and antimicrobial activity. Molecules15 (4), 2203–2210 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.